Tina Licina
Optometrist · Las Vegas, NVNPI 1457703340
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.4% of the total across 156 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 24.5% of the total. Reporting peaked in 2019 at $2,452 and has fallen 61.1% since, to $954 in 2025. Among optometrist clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 156 payments — averaging $43.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Glaukos Corporation$918
- Bausch & Lomb, A Division Of Bausch Health US, LLC$846
- Aerie Pharmaceuticals, Inc.$775
- Rxsight Inc$435
- Sun Pharmaceutical Industries Inc.$416
- plus $2K from 14 others
Across 4 payments — averaging $1899.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$8K
What the payments were for
- Consulting fees$5007%
- Food & beverage$6,31992%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 68 | $1,678 |
| Glaukos Corporation | 11 | $918 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 18 | $846 |
| Aerie Pharmaceuticals, Inc. | 6 | $775 |
| Rxsight Inc | 6 | $435 |
| Sun Pharmaceutical Industries Inc. | 8 | $416 |
| Alcon | 6 | $413 |
| Oyster Point Pharma, Inc. | 8 | $317 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $246 |
| Tarsus Pharmaceuticals, Inc. | 2 | $234 |
| Novartis | 4 | $176 |
| Shire North American Group Inc | 2 | $141 |
| Amgen(2 entities) | 4 | $70 |
| Mallinckrodt Hospital Products Inc. | 2 | $46 |
| Bausch & Lomb Americas Inc. | 2 | $37 |
| Kala Pharmaceuticals, Inc. | 2 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Dompe US, Inc. | 1 | $18 |
| Sight Sciences, Inc. | 1 | $16 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$751
- RXSIGHT CONTACT LENS$380
- RXSIGHT INJECTOR CARTRIDGE$380
- RXSIGHT INJECTOR HANDPIECE$380
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$380
- VYZULTA$350
- iAccess Precision Blade$282
- LIGHT ADJUSTABLE LENS (LAL)$266
- ENVISTA$255
- RESTASIS$250
- XDEMVY$234
- Tecnis Simplicity$228
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$165
- iDose$155
- iStent$153
- TYRVAYA$150
- XEN$148
- Photrexa Viscous and Photrexa$134
- CEQUA$125
- XIIDRA$125
How this compares
$6,838 in reported general payments places this provider in the 95th percentile of 494 optometrist providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 207 | $239,431 |
| LumiganBimatoprost | 241 | $129,647 |
| XiidraLifitegrast | 29 | $36,132 |
| VyzultaLatanoprostene Bunod | 25 | $13,132 |
| Cyclosporine | 17 | $8,546 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 63 | $8,541 |
| Latanoprost | 571 | $4,816 |
| Alphagan PBrimonidine Tartrate | 11 | $4,011 |
| Prednisolone Acetate | 39 | $1,800 |
| Dorzolamide Hcl | 86 | $1,608 |
| Timolol Maleate | 233 | $1,531 |
| Travoprost | 21 | $1,486 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 85 | $1,171 |
| ErythromycinErythromycin Base | 89 | $879 |
| Brimonidine Tartrate | 99 | $621 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $1,678 | $373,089459 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $37 | $49,26454 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 494 optometrist providers in Nevada.
Other optometrist in Las Vegas
- Eric BrookerLas Vegas$53K
- My VuongLas Vegas$47K
- Chen YoungLas Vegas$46K
- Harlan KopolowLas Vegas$36K
- Jenny WongLas Vegas$34K
- Adam SchwartzLas Vegas$26K
- Lawrence WangLas Vegas$12K
- Brian MillerLas Vegas$11K
- Mark MillerLas Vegas$8K
- Victoria MarLas Vegas$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.